Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aptus Pharma Limited has informed the BSE that its trading window for dealing in company securities will remain closed from April 01, 2026 until 48 hours after the declaration of financial results for the half year and full year ended March 31, 2026. This closure is a routine compliance measure under the company's Code of Conduct for Prohibition of Insider Trading. During this period, designated persons such as directors, promoters, and key employees are barred from trading in the company's shares. The announcement was signed by Managing Director Tejash Hathi (DIN: 03151221) on March 28, 2026.
This is a standard regulatory disclosure with no direct impact on share price. However, it signals that the company's audited annual results for FY26 and half-yearly results are imminent, which may bring clarity on earnings and could influence sentiment once declared.